Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada. more
Time Frame | CYBN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.76% | -0.09% | 0.83% |
1-Month Return | 3.06% | 0.03% | 5.98% |
3-Month Return | 17.3% | -6.26% | 9.65% |
6-Month Return | -17.33% | 1.16% | 14.29% |
1-Year Return | -38.6% | 11.16% | 32.26% |
3-Year Return | -78.22% | 11.98% | 31.61% |
5-Year Return | -79.26% | 47.19% | 94.03% |
10-Year Return | -79.26% | 109.06% | 191.47% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 864.00K | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Cost of Revenue | - | 664.00K | 168.00K | 251.00K | 424.00K | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":25.3,"profit":true},{"date":"2023-03-31","value":37.8,"profit":true},{"date":"2024-03-31","value":63.86,"profit":true}] |
Gross Profit | - | 200.00K | (168.00K) | (251.00K) | (424.00K) | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":-84,"profit":false},{"date":"2023-03-31","value":-125.5,"profit":false},{"date":"2024-03-31","value":-212,"profit":false}] |
Gross Margin | - | 23.15% | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":null,"profit":false},{"date":"2023-03-31","value":null,"profit":false},{"date":"2024-03-31","value":null,"profit":false}] |
Operating Expenses | 1.94M | 30.72M | 63.84M | 51.52M | 78.84M | [{"date":"2020-03-31","value":2.47,"profit":true},{"date":"2021-03-31","value":38.97,"profit":true},{"date":"2022-03-31","value":80.98,"profit":true},{"date":"2023-03-31","value":65.35,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Operating Income | (1.95M) | (30.46M) | (63.60M) | (54.94M) | (78.84M) | [{"date":"2020-03-31","value":-195360000,"profit":false},{"date":"2021-03-31","value":-3046400000,"profit":false},{"date":"2022-03-31","value":-6359700000,"profit":false},{"date":"2023-03-31","value":-5494300000,"profit":false},{"date":"2024-03-31","value":-7883600000,"profit":false}] |
Total Non-Operating Income/Expense | - | (1.14M) | (3.55M) | 4.63M | 1.38M | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-24.51,"profit":false},{"date":"2022-03-31","value":-76.7,"profit":false},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":29.69,"profit":true}] |
Pre-Tax Income | (1.94M) | (32.22M) | (67.63M) | (47.49M) | (78.08M) | [{"date":"2020-03-31","value":-194400000,"profit":false},{"date":"2021-03-31","value":-3222000000,"profit":false},{"date":"2022-03-31","value":-6763100000,"profit":false},{"date":"2023-03-31","value":-4749000000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false}] |
Income Taxes | 9.60 | 10.00K | 3.79M | (7.45M) | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":0.26,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-196.49,"profit":false},{"date":"2024-03-31","value":"-","profit":true}] |
Income After Taxes | - | (32.23M) | (71.42M) | (40.04M) | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-3223000000,"profit":false},{"date":"2022-03-31","value":-7142400000,"profit":false},{"date":"2023-03-31","value":-4003700000,"profit":false},{"date":"2024-03-31","value":"-","profit":true}] |
Income From Continuous Operations | - | (32.22M) | (67.63M) | (47.49M) | (78.08M) | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-3222000000,"profit":false},{"date":"2022-03-31","value":-6763100000,"profit":false},{"date":"2023-03-31","value":-4749000000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | (1.94M) | (32.22M) | (71.42M) | (40.04M) | (78.08M) | [{"date":"2020-03-31","value":-194400000,"profit":false},{"date":"2021-03-31","value":-3222000000,"profit":false},{"date":"2022-03-31","value":-7142400000,"profit":false},{"date":"2023-03-31","value":-4003700000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false}] |
EPS (Diluted) | - | (0.18) | (0.40) | (0.26) | (0.23) | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-18,"profit":false},{"date":"2022-03-31","value":-40,"profit":false},{"date":"2023-03-31","value":-26,"profit":false},{"date":"2024-03-31","value":-23,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CYBN | |
---|---|
Cash Ratio | 20.93 |
Current Ratio | 24.24 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CYBN | |
---|---|
ROA (LTM) | -32.71% |
ROE (LTM) | -49.07% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CYBN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CYBN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 278.25 |
P/B | 1.16 |
Price/FCF | NM |
EV/R | 313.59 |
EV/Ebitda | NM |
Cybin Inc (CYBN) share price today is $10.43
Yes, Indians can buy shares of Cybin Inc (CYBN) on Vested. To buy Cybin Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CYBN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cybin Inc (CYBN) via the Vested app. You can start investing in Cybin Inc (CYBN) with a minimum investment of $1.
You can invest in shares of Cybin Inc (CYBN) via Vested in three simple steps:
The 52-week high price of Cybin Inc (CYBN) is $19.84. The 52-week low price of Cybin Inc (CYBN) is $6.5.
The price-to-earnings (P/E) ratio of Cybin Inc (CYBN) is
The price-to-book (P/B) ratio of Cybin Inc (CYBN) is 1.16
The dividend yield of Cybin Inc (CYBN) is 0.00%
The market capitalization of Cybin Inc (CYBN) is $211.31M
The stock symbol (or ticker) of Cybin Inc is CYBN